CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 176 enrolled
Drug / intervention
Talarozoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00716144
NCT00716144Phase 2Completed
CompareCT.gov

A Randomized, Evaluator-Blind, Placebo-Controlled, Parallel-Group Dose-Ranging Study of the Safety and Efficacy of Oral R115866 and R115866 Placebo in the Treatment of Plaque Psoriasis

Stiefel, a GSK Company·interventional·Posted Jul 16, 2008·Updated Jan 29, 2018

In Brief

A Phase 2 clinical trial evaluating Talarozole for Psoriasis. Completed, enrolled 176 participants across 22 sites in 5 countries.

Detailed Summary

Eligible subjects will be randomly assigned to one of three dose regimens of oral R115866 or placebo for the treatment of severe plaque psoriasis for 12 twelve weeks. The safety and efficacy of R115866 will be evaluated during the treatment period and the 8-week post treatment follow-up period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesGermany, Ireland, Netherlands, Russia, United Kingdom
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 16, 2008
Enrollment StartJun 1, 2006
Primary CompletionMay 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.0 years ago

Interventions

Talarozoledrug

Oral Capsule Once Daily